GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.

According to the Centers for Disease Control and Prevention, bird flu was detected in 254 dairy herds across 14 states.

Including the most recent two cases in California, 16 human cases of H5 have been reported in the United States during 2024, bringing the total to 17 cases since 2022.

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains ...

Full story available on Benzinga.com